In a report released today, Brian Kinstlinger from Maxim Group reiterated a Buy rating on Applied DNA Sciences (NASDAQ: APDN), with a price target of $5. The company’s shares closed yesterday at $1.54.
“APDN has granted Colorcon exclusive worldwide rights to use its molecular tags and other supply chain authentication technologies in film coatings for solid oral dosage applications.”
According to TipRanks.com, Kinstlinger is a 1-star analyst with an average return of -0.7% and a 49.7% success rate. Kinstlinger covers the Technology sector, focusing on stocks such as Helios & Matheson North America Inc, BIO-key International Inc, and Caci International.
Applied DNA Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $5.
Based on Applied DNA Sciences’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $647.7K and GAAP net loss of $3.18 million. In comparison, last year the company earned revenue of $905.4K and had a GAAP net loss of $3.43 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Applied DNA Sciences, Inc. engages in the security solutions. It provides biotechnology-driven solutions to help protect products, brands, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.